Interstitial lung disease progression in patients with anti-aminoacyl transfer-RNA-synthetase autoantibodies is characterized by higher levels of sCD163.

Autor: Ramos-Martínez E; Experimental Medicine Research Unit, Facultad de Medicina, Universidad Nacional Autónoma de México 06720 México City Mexico., Falfán-Valencia R; HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, México City 14080, Mexico., Pérez-Rubio G; HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, México City 14080, Mexico., Mejía M; Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ismael Cosío Villegas, Calz. Tlalpan 4502, Sección XVI, Tlalpan, México City, Ciudad de México 14080, Mexico., Mejía-Hurtado JG; Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ismael Cosío Villegas, Calz. Tlalpan 4502, Sección XVI, Tlalpan, México City, Ciudad de México 14080, Mexico., Buendía-Roldán I; Translational Research Laboratory on Aging and Pulmonary Fibrosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, México City 14080, Mexico., González-Pérez MI; Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ismael Cosío Villegas, Calz. Tlalpan 4502, Sección XVI, Tlalpan, México City, Ciudad de México 14080, Mexico., Mateos-Toledo HN; Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ismael Cosío Villegas, Calz. Tlalpan 4502, Sección XVI, Tlalpan, México City, Ciudad de México 14080, Mexico., Rojas-Serrano J; Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ismael Cosío Villegas, Calz. Tlalpan 4502, Sección XVI, Tlalpan, México City, Ciudad de México 14080, Mexico; Profesor, Programa de Maestría y Doctorado en Ciencias Médicas, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 14080, Mexico. Electronic address: jrojas@iner.gob.mx.
Jazyk: angličtina
Zdroj: Immunology letters [Immunol Lett] 2022 Aug; Vol. 248, pp. 56-61. Date of Electronic Publication: 2022 Jun 18.
DOI: 10.1016/j.imlet.2022.06.007
Abstrakt: Background: Patients with anti-tRNA autoantibodies are characterized by arthritis, mechanic´s hands, fever, Raynaud´s phenomenon, and interstitial lung disease (ILD), in at least two clinical scenarios: the antisynthetase syndrome (ASSD) and interstitial pneumonia with autoimmune features (IPAF). The anti-tRNA-ILD treatment is centered on the administration of corticosteroids and a wide variety of immunosuppressive drugs; however, the effectiveness of the treatment depends on factors not fully understood. This research work aimed to quantify the serum levels of two molecules related to pulmonary fibrosis and explore their relationship with the progression of ILD associated with ASSD METHODOLOGY: Serum levels of sCD163 and TGF-β1 from baseline and after six months of treatment of ILD patients' positives to anti-tRNA were included in the current study. At six months, patients were classified as with or without ILD progression RESULTS: Forty patients were included (anti-Jo1, anti-PL7, anti-PL12, and anti-Ej). Five patients (12.5%) had ILD progression and were characterized by higher levels of sCD163 at baseline. Baseline sCD163 serum levels showed good discriminatory capacity in patients with ILD progression. On the other hand, at follow-up, serum TGF-β1 levels significantly increased in both patients' groups, with and without progression CONCLUSION: Basal levels of sCD163 were higher in patients who later developed ILD progression and kinetics of both molecules suggests the participation of M2 macrophages in the development of ILD.
(Copyright © 2022. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: